Podcasts about Medical research

When neuroscientist Madeline Lancaster was a brand new postdoc, she accidentally used an expired protein gel in a lab experiment and noticed something weird. The stem cells she was trying to grow in a dish were self-assembling. The result? Madeline was the first person ever to grow what she called a “cerebral organoid,” a tiny, 3D version of a human brain the size of a peppercorn.In about a decade, these mini human brain balls were everywhere. They were revealing bombshell secrets about how our brains develop in the womb, helping treat advanced cancer patients, being implanted into animals, even playing the video game Pong. But what are they? Are these brain balls capable of sensing, feeling, learning, being? Are they tiny, trapped humans? And if they were, how would we know?Special thanks to Lynn Levy, Jason Yamada-Hanff, David Fajgenbaum, Andrew Verstein, Anne Hamilton, Christopher Mason, Madeline Mason-Mariarty, the team at the Boston Museum of Science, and Howard Fine, Stefano Cirigliano, and the team at Weill-Cornell. EPISODE CREDITS: Reported by - Latif Nasserwith help from - Mona MadgavkarProduced by - Annie McEwen, Mona Madgavkar, and Pat Walterswith mixing help from - Jeremy BloomFact-checking by - Natalie Middleton and Rebecca Randand Edited by  - Alex Neason and Pat WaltersEPISODE CITATIONS:Videos - “Growing Mini Brains to Discover What Makes Us Human,” Madeline Lancaster's TEDxCERN Talk, Nov 2015 (https://zpr.io/6WP7xfA27auR)Brain cells playing Pong (https://zpr.io/pqgSqguJeAPK)Reuters report on CL1 computer launch in March 2025 (https://zpr.io/cdMf8Yjvayyd) Articles - Madeline Lancaster: The accidental organoid – mini-brains as models for human brain development (https://zpr.io/nnwFwUwnm2p6), MRC Laboratory of Molecular Biology What We Can Learn From Brain Organoids (https://zpr.io/frUfsg4pxKsb), by Carl Zimmer. NYT, November 6, 2025Ethical Issues Related to Brain Organoid Research (https://zpr.io/qyiATHEhdnSa), by Insoo Hyun et al, Brain Research, 2020 Brain organoids get cancer, too, opening a new frontier in personalized medicine (https://zpr.io/nqMCQ) STAT Profile of Howard Fine and his lab's glioblastoma research at Weill Cornell Medical Center: By re-creating neural pathway in dish, Stanford Medicine research may speed pain treatment (https://zpr.io/UnegZeQZfqn2) Stanford Medicine profile of Sergiu Pasca's research on pain in organoids A brief history of organoids (https://zpr.io/waSbUCSrL9va) by Corrò et al, American Journal of Physiology - Cell Physiology, Books - Carl Zimmer Life's Edge: The Search for What it Means to be Alive (https://carlzimmer.com/books/lifes-edge/)Sign up for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Signup (https://radiolab.org/newsletter)!Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today.Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

This week, we explore new options in cardiovascular prevention, fish-oil supplementation in dialysis patients, RSV vaccination, and cutting-edge cellular therapy for leukemia. We discuss advances in lung cancer treatment, approaches to functional dyspepsia, and a complex case of severe infection after travel. Perspectives examine access to and cost of weight-loss drugs, the promise and risks of AI in clinical care, and what it means to care for others while carrying personal loss.

In the last year, you've basically replaced your body weight in new cells. So yes, it's a new year, new you. To ring in 2026, we're talking about starting anew, and drawing inspiration from tiny worms that embody the ultimate growth mindset—they can regrow a whole body from just a tiny piece of their tail. In this festive episode, Host Flora Lichtman talks with biologist Alejandro Sánchez Alvarado, a pioneer in the field of regeneration, about the science of regeneration and the biology lessons we can carry into the new year. Guest: Dr. Alejandro Sánchez Alvarado is a biologist and president and chief scientific officer of the Stowers Institute for Medical Research in Kansas City, Missouri.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

In this week's episode we've pulled a vault recording from 2025! Blood editor Dr. Laurie Sehn interviews authors Drs. David-Alexandre Trégouët and Johannes Schetelig on their research published in volume 146 issue 19 of Blood journal. Dr. Trégouët's study conducted a genome-wide association study supplemented by transcriptome and Mendelian randomization analyses to identify 28 loci and proteins associated with VTE recurrence risk. This work provides genomic evidence that inherited variants contribute to the risk of VTE recurrence, raising the possibility of a more personalized approach to the prevention of recurrent VTE. The study conducted by Dr. Schetelig and colleagues report the results of a long term trial on patients with poor-response AML, comparing outcomes between patients who received salvage chemotherapy versus immediate transplantation. With no difference in survival rates at 5 years, outcomes seem to be determined mainly by genetic risk factors, age, and comorbidities, therefore challenging the routine use of intensive remission induction before allogeneic transplant in patients with an available donor and underscore the need for novel therapeutic strategies for poor-risk AML.Featured Articles:Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial 

This week, we share advances in treatment for EGFR-mutated lung cancer, a brain-penetrant enzyme therapy for a rare pediatric disorder, and dual targeting of extramedullary myeloma. We review cardiogenic shock, work through a challenging diagnostic puzzle in a young woman with recurrent illness, and explore Perspectives on corporatized care, vaccine policy, AI in medicine, and where clinicians carry grief.

In this week's episode, Blood editor Dr. James Griffin interviews authors Drs. Vincent Muczynski and Mark Geyer on their latest research published in Blood. Dr. Muczynski's research asks if there could there be a better gene than the factor VIII (FVIII) gene to transfer for curative treatment of hemophilia A? Dr. Geyer then explores CAR T cells armed with interleukin-18 (IL-18) secretion that target CD371, a transmembrane glycoprotein with high expression on AML and leukemia-initiating cells. Both studies explore finding novel targets for these powerful treatment modalities. Featured Articles:Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibodyCD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia

State Regulations Threaten Dietary Supplements: Iron Radio Hosts Discuss the ImpactIn this episode of Iron Radio, hosts Coach Phil Stevens, Dr. Lonnie Lowery, and Dr. Mike T. Nelson discuss a recent article by Kyle Turk concerning the growing legislative efforts by states to restrict dietary supplements, notably those used in strength sports. The discussion covers the impact of these regulations on consumer access to supplements like creatine and caffeine, the historical context of such laws, and the potential future of supplement availability. The hosts also touch on the broader implications for research and individual responsibility in navigating supplement choices.01:11 Discussion on Dietary Supplements01:30 State Legislation Impact on Supplements02:50 Consumer Perspective on Supplement Bans03:09 Historical Context and Regulatory Changes03:59 Creatine and Misconceptions06:14 Debate on Supplement Regulation07:39 Pharmaceutical Influence and Market Dynamics12:08 Personal Responsibility vs. Regulation14:12 Understanding Public Education and Legitimate Sources14:53 Evaluating Health Information Online16:06 Challenges in Medical Research and Regulation17:27 Funding and Research Biases20:52 Legal and Regulatory Issues in Supplementation Donate to the show via PayPal HERE.You can also join Dr Mike's Insider Newsletter for more info on how to add muscle, improve your performance and body comp - all without destroying your health, go to www.ironradiodrmike.com Thank you!Phil, Jerrell, Mike T, and Lonnie

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Recognizing that life has an expiration date makes both medicine and risk-taking more meaningful, and that insight runs through this entire conversation.  In this episode, Dr. Orvil Martinez, CEO of the Advanced Medical Research Center, and Dr. Felix Rivera, owner of US Neurology Consulting, discuss how their Puerto Rican roots, love of adventure, and passion for technology influence their medical practice and vision for the future of healthcare. They share wild stories of skydiving from airplane wings, bungee jumping over concrete, and near-fatal injuries, set against the backdrop of their lives as thoughtful clinicians, parents, and technophiles. The conversation then turns to AI's potential to ease primary care burdens in Puerto Rico, support tele-neurology, reduce overhead, and sustain independent practice. They close by unveiling plans for the island's first AI Congress in November 2026, underscoring that innovation, trust, and accepting mortality are essential to living fully. Tune in and learn how personal risk, family roots, and bold AI vision are converging to reshape care in Puerto Rico and beyond! Resources Connect with and follow Dr. Orvil Martinez on LinkedIn. Visit the Advanced Medical Research Center website. Follow and connect with Dr. Felix Rivera on LinkedIn.

In this week's episode, Blood editor Dr. Laurie Sehn interviews three of the latest Blood authors: Drs. Vijay Sankaran, Ruud Delwel, Françoise Kraeber-Bodere. Two studies on the MECOM gene have been paired in this episode, analyzing new groundwork for potential novel myeloid differentiation therapies via repression of MECOM restoring enhancer mediated CEBPA expression. We'll also hear about the results of CASSIOPET, imaging companion study of the CASSIOPEIA trial, and how achieving negativity in PET before starting maintenance therapy is significant even in patients who still show residual disease in the bone marrow.Featured ArticlesCEBPA repression by MECOM blocks differentiation to drive aggressive leukemiasMECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed from the CASSIOPEIA trial

This week, we look at ctDNA-guided immunotherapy for bladder cancer, cardiovascular outcomes with tirzepatide, and evidence that one HPV vaccine dose may be enough. We explore high-dose rifampin for tuberculous meningitis, review measles amid rising outbreaks, and follow a challenging case of gastrointestinal bleeding. Essays examine how clinicians navigate post-Dobbs care, tobacco harm among people with mental illness, congenital syphilis, and sustaining medical research.

The recovery conversation continues between 20-Minute Health Talk host Sandra Lindsay and Andrew Drazan, founder and CEO of Wellbridge, and Edmond Hakimi, DO, its medical director. They discuss the long road recovery can take and how relapses are a natural part of the recovery process. They also explore the different paths to recovery that Wellbridge can tailor to their patients' needs; why removing the moral stigma of addiction is so critical to finding addiction solutions; what it was like to launch Wellbridge during Covid, and much more. This is Part 2 of this series. Listen to Part 1 About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities.   Facebook –   / northwellhealth   Instagram -   / northwellhealth   X - https://www.x.com/northwellhealth LinkedIn - https://www.linkedin/northwellhealth This is Part 2 of this series. Listen to Part 1 About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities.   Facebook –   / northwellhealth   Instagram -   / northwellhealth   X - https://www.x.com/northwellhealth LinkedIn - https://www.linkedin/northwellhealth  

There are a number of programs in healthcare industry that pay patients money to participate in research projects. From the perspective of a potential patient participant, paid participation in medical surveys, focus groups, and other research projects can offer several benefits. Firstly, it provides an opportunity to contribute to medical Read More Shared by United Resource Connection December 12, 2025

What are your thoughts on the benefits of magnesium threonate?Is creatine helpful in building bone strength in osteoporosis?What are your thoughts on the REMS ultrasound to diagnose bone mineral density status?What should I do about my PSA, which appears to be trending upward?  Are my diabetes meds causing erectile dysfunction?Does maltodextrin spike blood glucose tremendously?

Antioxidants and resistance training for treatment of sarcopeniaAnabolic resistance with advancing ageAre there any holistic medicine approaches to treating Lewy Body Syndrome?Is canned fish like sardines safe to eat?

In this Review Series episode, Blood Associate Editor, Dr. Elisabeth Battinelli discusses the Platelet Heterogeneity with authors Drs. Craig Morrell, Larry Frelinger, and Leo Nicolai.  Find the full review series in volume 146 issue 24 of Blood. 

This week, we look at new studies on high-dose influenza vaccines for older adults, antiplatelet therapy after coronary surgery, and HER2-targeted immunotherapy for advanced bladder cancer. We review complex regional pain syndrome and a pediatric case of fever and rash. We also explore FDA innovation and safety, aspirin's role in metastasis prevention, the meaning of “the good doctor,” smallpox in the Revolution, and how AI may reshape medical science.

In this episode of 20-Minute Health Talk, host Sandra Lindsay explores the complex landscape of addiction and recovery with Andrew Drazan, founder and CEO of Wellbridge, and Edmond Hakimi, DO, its medical director. Journey through Drazan's personal history and the inspiration behind Long Island's premier treatment center. Discover the science behind addiction as Dr. Hakimi explains how genetic, environmental, and neurological factors interact to fuel substance use disorders. Learn about Wellbridge's holistic approach to individualized care, blending medical expertise with therapeutic activities like art and exercise to help patients build a sustainable recovery path.  About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 28 hospitals, 890 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit the health system's job portal and explore our many opportunities.  

Taken as a group, blood cancers are the fifth most common type of cancer in New Zealand - affecting around one in twenty people during their lifetime. But some patients are forced to seek help overseas because a treatment that could save them isn't available here. The Wellington based Malaghan Institute of Medical Research is working to change that. Winner of this year's Breakthrough Project category in the KiwiNet Awards, Malaghan is currently conducting phase two of its CAR-T cell therapy clinical trials. The therapy essentially uses the body's own immune system to target and kill cancer cells. Professor Robert Weinkove is the Clinical Director and he speaks to Mihi about the next major step in their push to make it a standard part of cancer care in New Zealand.

In this special episode, Blood editor Dr. Laura Michaelis interviews Dr. Arielle Langer and Blood Associate editor Dr. Marc Blondon for this special Maternal Health episode. In honor of the second Maternal Health compendium, both discuss their papers featured in this special collection. Featured Articles: β-Thalassemia minor is associated with high rates of worsening anemia in pregnancyLongitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptivesSee the entire Maternal Health Compendium Second Edition

In this bonus episode of 20-Minute Health Talk, host Sandra Lindsay speaks with filmmaker Richard LaRochelle, who also works with Northwell's community health program. LaRochelle filmed a conversation with four prostate cancer survivors, including former New York Knicks player Allan Houston, with the goal of raising awareness about prostate cancer among the black community. LaRochelle shares his experience in making the short film and what he hopes audiences will learn from the men's experiences.  View The Unspoken Truth: A Dialogue on Prostate Cancer Among Black Men. This bonus episode is Part 4 of this series. Listen to Part 1  Listen to Part 2  Listen to Part 3 About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities.   Facebook –   / northwellhealth   Instagram -   / northwellhealth   X - https://www.x.com/northwellhealth LinkedIn - https://www.linkedin/northwellhealth

 In this week's episode, Blood editor Dr. James Griffin speaks with Drs. Emanuele Zucca and Sandra Pinho about their latest articles published in Blood. Dr. Zucca discusses his second analysis of the IELSG37 trial, where findings suggested that R-CHOP21 rituximab, cyclophosphamide,doxorubicin, vincristine, and prednisone, administered every 21 days) may be a suboptimal frontline regimen for PMBCL. Dr. Pinho discusses the aging megakaryocytic niche and its influence on the age-associated decline in HSC and progenitor cell function. The authors demonstrate that remodeling of the megakaryocytic niche and associated platelet factor 4 (PF4) downregulation are central mechanisms driving HSC aging.Featured Articles: Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging 

Maryanne Demasi is an independent investigative journalist based in Australia and a former medical scientist with a PhD in rheumatology from the University of Adelaide.For many years, she worked for the Australian Broadcasting Corporation (ABC) and gained wide attention for reporting on controversial medical topics, particularly the efficacy and safety of statins and psychiatric drugs.Demasi was eventually suspended from her position at ABC in 2016 following controversies over her comprehensive and critical examination of statin drugs and other health risks. After leaving ABC, she continued her career as an independent investigative medical journalist.In this interview, we discuss how science can be weaponized and drug data manipulated or suppressed, even for many common drugs prescribed to millions of Americans.“Psychiatry is a classic example of where pharmaceutical companies have been sponsoring their own trials and burying data and then putting a spin on the medical journal, saying that the drug is safe and effective when the fact is, it's not,” she says.“This is not an exception. This happens commonly. Throughout history, pharmaceutical companies have been sued for designing trials [and] hiding, burying data.”Demasi said she has been censored during her career as a journalist and understands the censorship and the pressures faced by journalists and medical professionals who challenge the data and narratives of the powerful pharmaceutical industry.“COVID was the unmasking of how all of this censorship came about,” she said. “It really was an event that woke people up to just how corrupt the system is at every level, from the media to the academia to the agencies that are meant to protect us to the medical journals.”Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.

This week, we look at new trials on glucocorticoids for pneumonia in Africa, shunting for normal-pressure hydrocephalus, and pegcetacoplan for two rare kidney diseases. We review updated vaccine evidence for Covid-19, RSV, and influenza, and present a case of respiratory decline and muscle weakness. Perspectives explore health care incentives, U.S. global health strategy, and bringing AI-enabled care to rural America.

Dr. Hoffman continues his conversation with Dr. Kevin J. Tracey, president and CEO at the Feinstein Institutes for Medical Research and author of "The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes.”

The Revolutionary Role of the Vagus Nerve in Bioelectronic Medicine: Dr. Kevin J. Tracey, president and CEO at the Feinstein Institutes for Medical Research and author of "The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes,” details the historical context and recent advancements in harnessing the power of the vagus nerve to control inflammation without causing immunosuppression. The conversation explores the journey from early experimental stages to the recent FDA approval for treating rheumatoid arthritis through vagus nerve stimulation (VNS) devices. He also delves into the potential applications of VNS in treating other inflammatory conditions, mood disorders, and the science behind non-invasive lifestyle techniques and commercially available devices. The episode provides valuable insights into the future of bioelectronic medicine and its potential to revolutionize medical treatments.

In this episode of 20 Minute Health Talk, host Sandra Lindsay delves into the emotional journey of prostate cancer from the unique perspectives of supportive partners. Joining her are two remarkable women, Mary Hillery and Tamara Houston, who share their experiences as caregivers alongside their husbands, prostate cancer survivors Tony Hillery and former New York Knicks player Allan Houston. Mary Hillery, a human resources expert, offers insights on resilience and caregiving. Tamara Houston, an educator and advocate for youth empowerment, speaks on the power of faith and familial support in challenging times.  This is Part 3 of this series. Listen to Part 1  Listen to Part 2  About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities.   Facebook –   / northwellhealth   Instagram -   / northwellhealth   X - https://www.x.com/northwellhealth LinkedIn - https://www.linkedin/northwellhealth

Find More Great Info From Dr. Melanie Matheu Here: SUBSTACK: https://lilscience.substack.com TIKTOK:https://www.tiktok.com/@laughterinlight YOUTUBE: https://www.youtube.com/@LaughterInLight Hawk talks with immunologist Dr. Melanie Matthew about the upcoming flu season and the devastating impact of RFK Jr as HHS Secretary. Australia experienced record-setting influenza deaths this year, with flu killing more people than COVID. The H3N2 variant mutated to evade vaccine protection, leading to unprecedented hospitalizations. Japan declared a flu epidemic five weeks early, and similar patterns are emerging in the United States.Dr. Matthew explains why flu vaccination remains critical despite mutations, reducing hospitalizations by 30-40% in adults and 70-75% in children. The conversation shifts to RFK Jr's anti-vaccine policies at HHS, where he claims no vaccine is safe and effective despite having zero background in immunology or pediatrics. His appointment, along with Marty Makary at FDA and Jay Bhattacharya at NIH, represents a complete rejection of scientific reality in favor of political ideology.The discussion covers RFK Jr's role in 88 child deaths in Samoa from measles, his vitamin A recommendations causing liver damage in Texas children, and how VAERS data is being misrepresented. Dr. Matthew details the exodus of top scientists from NIH, cancelled research grants, and terminated clinical trials that will kill patients. Forever chemicals (PFAS) are being approved for pesticides while vaccine research funding gets slashed.America faces losing measles elimination status, rising preventable disease deaths, and compromised pandemic preparedness. The CDC's COVID vaccine guidance for pregnant women has been offline for months despite evidence linking infection to preterm births and neurological damage. This administration prioritizes grift over public health, with consequences spanning decades. SUPPORT & CONNECT WITH HAWK- Support on Patreon: https://www.patreon.com/mdg650hawk- Support Hawk's Merch Store: https://hawkmerchstore.com- Connect on TikTok: https://www.tiktok.com/@hawkeyewhackamole- Connect on BlueSky: https://bsky.app/profile/mdg650hawk.bsky.social- Connect on YouTube: https://www.youtube.com/@hawkpodcasts ALL HAWK PODCASTS INFO- Additional Podcasts Available Here: https://www.hawkpodcasts.com- Listen to Hawk Podcasts On Your Favorite Platform:Spotify: https://spoti.fi/3RWeJfyApple Podcasts: https://apple.co/422GDuLYouTube: https://youtube.com/@hawkpodcastsiHeartRadio: https://ihr.fm/47vVBdPPandora: https://bit.ly/48COaTBSimplecast: https://hawk-droppings.simplecast.com- Hawk Podcasts RSS Feed: https://feeds.simplecast.com/pPVtxSNJ

Patrick Vallance, the minister for science, research and innovation, recently unveiled a plan to cut animal testing through greater use of AI and other technologies, with the eventual aim of phasing it out altogether. To understand how this will affect research and what could be used in place of animal models, Madeleine Finlay hears from science editor Ian Sample, Prof Hazel Screen of Queen Mary University London and Prof Kevin Harrington from the Institute of Cancer Research. Help support our independent journalism at theguardian.com/sciencepod

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.Featured ArticlesFixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular LymphomaPre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT

This week, we look at new studies on early aspirin discontinuation after myocardial infarction, an antiviral pill for dengue prevention, and CRISPR-based gene editing for lipid disorders. We review bedside clinical teaching and present a complex case of seizures and visual disturbances. Perspectives explore antidepressant safety in pregnancy, restoring trust in public health, academic medical centers' venture investments, and a young physician's wrinkled white coat.

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new therapeutic approach to von Willebrand disease with the development of a novel bispecific antibody (KB-V13A12) that links endogenous mouse VWF to albumin, extending VWF half-life twofold with cessation of provoked bleeding. Dr Parker shares the results of a 43-patient phase 2 study that evaluates the single agent isatuximab, a CD38 monoclonal antibody, in patients with relapsed/refractory AL amyloidosis. With a hematological response rate of 77%, organ response rates between 50 and 57%, and an excellent safety profile, the current study lays the foundation for future use of isatuximab across treatment settings and combination strategies.Featured ArticlesIsatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)A bispecific nanobody for the treatment of von Willebrand disease type 1

This week, we look at new research on potassium optimization in patients with defibrillators, reducing antihypertensive therapy in nursing homes, an mRNA influenza vaccine, and belzutifan for rare neuroendocrine tumors. We review long QT syndrome and present a case of abnormal behavior and seizures in a young man. We also explore perspectives on primary care reform, tobacco cessation in HIV and tuberculosis care, corporate control in health care, and the simple power of compassion with ice cream.

After the discovery of a new gene therapy for Huntington's, a devastating brain disease, Datshiane Navanayagam talks to one of the women in the UK who worked on it and a biologist from India who's made recent discoveries that could improve treatment for TB, which still kills over a million people globally each year.Anne Rosser is Professor of Clinical Neuroscience at Cardiff University, combining both academic and clinical work specialising in patients with Huntington's Disease. Huntington's is an inherited condition caused by a faulty gene which stops the brain working properly, affecting mobility, learning, thinking and emotions. Anne also directs the Brain Repair Group in Cardiff.Paridhi Sukheja is lead biologist for Tuberculosis drug discovery at Calibr-Skaggs Institute at Scripps Research in the US – a nonprofit research institute looking at drug discovery and treatments for diseases. TB is one of the world's deadliest infectious diseases and, while widely treatable, it still kills 1.2 million people a year. Part of this is due to increasingly drug-resistant strains of the disease. Paridhi's work has been instrumental in the discovery of a potential new treatment for TB, including drug-resistant strains.Produced by Jane Thurlow(Image: (L) Paridhi Sukheja credit Nick Cusato. (R), Anne Rosser courtesy Anne Rosser.)

Bioelectronic medicine is changing how we treat inflammation, autoimmunity, and chronic disease, and this episode shows you exactly how nerve stimulation could redefine human performance, longevity, and brain optimization. You will learn how electricity, neurotransmitters, and targeted neural pathways can replace drugs, control inflammation, and help you hack the vagus nerve with precision instead of guesswork. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey is joined by Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes for Medical Research at Northwell Health, pioneer of vagus nerve research, and author of The Great Nerve. He is one of the world's most cited scientists in inflammation and neuroscience, and his discoveries created the field now known as bioelectronic medicine. He identified the therapeutic action of anti TNF antibodies, mapped the inflammatory reflex, and revealed how vagus nerve signaling controls immunity. With more than 450 scientific publications and over 120 U.S. patents, he is a trusted authority whose work drives the future of anti-aging, functional medicine, metabolism, and neural therapies. Dr. Tracey and Host Dave Asprey explore how the vagus nerve truly operates, why it contains 200,000 fibers with different functions, and what happens when you stimulate specific pathways that regulate inflammation, HRV, neurotransmitters, and immune signaling. You will learn how nerve impulses transmit information, how voltage gated ion channels shape behavior and biology, and why certain forms of stimulation create measurable improvements in mitochondria, metabolic control, sleep optimization, and emotional regulation. They break down the science behind surgical vagus nerve implants, focused ultrasound, gamma entrainment, cytokine control, and real neuromodulation. They also explore why cold plunging, breath work, HRV training, nootropics, and consumer devices vary so widely in their effects, and how to evaluate these tools with practical biohacking frameworks. You will hear what actually works, what remains experimental, and what the next decade of nerve based therapies could unlock for brain optimization, longevity, ketosis, fasting, supplements, and AI guided interventions in human biology. You'll Learn: • How vagus nerve stimulation reduces inflammation through the inflammatory reflex • Why bioelectronic medicine can replace drugs in autoimmune conditions • How nerve fibers relay electrical and chemical signals inside the body • Why cold immersion, breath work, and HRV training activate specific vagal pathways • How 40 hertz gamma entrainment may influence cognitive decline • Which stimulation methods have clinical validation and which do not • Why high vagal tone is linked to better metabolism, immunity, and emotional stability • What future nerve based technologies may unlock for human performance Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Kevin J. Tracey, vagus nerve stimulation, bioelectronic medicine, inflammatory reflex, SetPoint Medical, cytokine control, neuromodulation therapy, autonomic nervous system, HRV optimization, inflammation reduction, rheumatoid arthritis treatment, focused ultrasound therapy, gamma entrainment, mitochondrial signaling, anti-aging science, neural pathway hacking, functional medicine research, immune system regulation, brain and body performance, human longevity science Thank you to our sponsors! -AquaTru | Go to https://aquatruwater.com/daveasprey and save $100 on all AquaTru water purifiers. -MASA Chips | Go to https://www.masachips.com/DAVEASPREY and use code DAVEASPREY for 25% off your first order. -Timeline | Head to https://www.timeline.com/dave to get 10% off your first order. -Calroy | Head to https://calroy.com/dave for an exclusive discount Resources: • Learn More About Kevin's Work: https://feinstein.northwell.edu/institutes-researchers/our-researchers/kevin-j-tracey-md • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 - Trailer 1:12 - Bioelectronic Medicine 3:23 - FDA Approval 6:48 - RA Treatment Explained 11:35 - Vagus Nerve Function 15:12 - External vs Implanted Stimulation 18:06 - Focused Ultrasound 26:11 - Ear Stimulation Science 30:51 - Clinical Evidence 37:10 - Alzheimer's Link 42:15 - Future Applications 46:48 - Cold Exposure Effects 53:51 - Common Misconceptions 55:38 - Final Thoughts See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this heartfelt episode of 20-Minute Health Talk, host Sandra Lindsay delves into the emotional journey of prostate cancer from the unique perspectives of supportive partners. Joining her are two remarkable women, Mary Hillery and Tamara Houston, who share their experiences as caregivers alongside their husbands, prostate cancer survivors Tony Hillery and former New York Knicks player Allan Houston. Mary Hillery, a human resources expert, offers insights on resilience and caregiving. Tamara Houston, an educator and advocate for youth empowerment, speaks on the power of faith and familial support in challenging times. Tune in to hear their powerful testimonies of love, partnership, and unwavering strength. About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 28 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit the health system's job portal and explore our many opportunities.  

BUFFALO, NY – November 17, 2025 – A new #research perspective was #published in Oncotarget (Volume 16) on November 14, 2025, titled “A personal perspective of patient-centred clinical trials.” In this perspective, led by corresponding author Jia Liu of The Kinghorn Cancer Centre, St Vincent's Hospital, the University of New South Wales, and the Garvan Institute of Medical Research, three early-phase clinical trial participants — Trevor Tyne, Elizabeth Ivimey, and Leanne Duggan — reflect on their personal experiences with experimental cancer treatments. Their stories offer a unique perspective on the patient journey through early-phase trials and emphasize the need to design clinical research that prioritizes patients' needs, dignity, and lived realities. The authors highlight both the life-changing opportunities that trials can provide and the systemic barriers that still prevent many patients from participating. This perspective captures a turning point in how early-phase trials are viewed. Once considered a last resort, these trials are now increasingly offered earlier in treatment, especially with the rise of biomarker-guided therapies. In this context, the patient experience has become critical. The authors outline key benefits of participation, including access to novel therapies, ongoing medical monitoring, emotional support, and a strong sense of purpose in contributing to future medical advancements. However, they also point out significant challenges, such as restrictive eligibility criteria, high financial and logistical burdens, and communication gaps between patients and trial staff. “While no trial guarantees success, the level of support, access to innovative therapies, and sense of contribution to medical progress can be profoundly meaningful.” Each narrative provides insight into the clinical trial experience. One patient explains how living with a visual impairment required tailored accessibility support throughout the trial process Another shares how genomic testing led to targeted treatment after standard options failed. Despite their different diagnoses and circumstances, all three stories reflect resilience, hope, and a shared call for trial designs that better reflect the realities of diverse patients. To address these issues, the authors propose a number of improvements to trial design and delivery. These include expanding eligibility criteria, offering financial and logistical assistance, improving communication training for research staff, and introducing dedicated trial navigators to help guide patients through complex processes. They also focus on the importance of involving patient advocates in trial design and ensuring smoother transitions for patients moving between treatment centers. While early-phase trials focus on safety and effectiveness, the authors argue they must also be guided by core values like ethics and patient empowerment. This perspective serves as a reminder that the future of cancer research depends not only on scientific innovation, but on an honest partnership between patients and the research community. By sharing these real-world experiences, the article encourages a broader conversation about how to make clinical trials more responsive to the people they are designed to serve. DOI - https://doi.org/10.18632/oncotarget.28776 Correspondence to - Jia Liu - jia.liu@svha.org.au Abstract video - https://www.youtube.com/watch?v=2CCGN78n8ug To learn more about Oncotarget, visit https://www.oncotarget.com: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Ian Sample joins Madeleine Finlay to discuss some of the most intriguing science stories from the week. They discuss the complicated legacy of James Watson, who won the Nobel Prize for the discovery of the structure of DNA; a new breakthrough in the quest to understand the autoimmune disease lupus; and why everyone from Joe Rogan to Kim Kardashian is talking about comet 3I/Atlas.. Help support our independent journalism at theguardian.com/sciencepod

In this week's episode, associate editor Dr. James Griffin interviews researchers Dr. John Semple and Dr. Othman Al-Sawaf on their groundbreaking studies on transfusion-related acute lung injury and chronic lymphocytic leukemia treatment. Dr. Semple explored how mitochondrial DNA could act as a first hit in lung injury, while Dr. Al-Sawaf revealed that patient fitness may not significantly impact the efficacy of targeted CLL treatments. Both studies challenge existing medical assumptions and suggest new approaches to understanding disease mechanisms and treatment responses.Featured ArticlesThe impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLMitochondrial DNA via recipient TLR9 acts as a potent first-hit in murine transfusion-related acute lung injury (TRALI)

Send us a textThis episode features Dr. Sofia Isabel Perazzo (Children's National Hospital) and Dr. Rakesh Rao (St. Louis Children's Hospital) discussing a CHNC Explore analysis of intestinal stricture formation following surgical necrotizing enterocolitis (NEC). Using 15 years of CHND data, they examined over 2,400 surgical NEC cases, finding an overall stricture incidence of about 31%, with striking inter-center variability (24–38%). Lower gestational age, stoma creation, and combined drainage-laparotomy increased risk, while peritoneal drainage was protective. Hispanic ethnicity was associated with lower risk. Although their predictive model (AUC 0.67) was modest, the findings offer valuable benchmarks for parent counseling, quality improvement, and hypothesis generation.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this episode, we look at new trials on deferring arterial catheterization in shock, beta-blocker use after myocardial infarction, and a treatment for triple-negative breast cancer. We review acromegaly. A case describes a man with dyspnea, edema, and pacemaker lead displacement. We explore perspectives on the burdens of primary care, the erosion of harm reduction, child health policy, and the meaning of hospice.

Send us a textWe trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab's Alzheimer's trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review.Journalist: Jessica Davis PlüssHost: Jo FahyAudio editor/video journalist: Michele AndinaDistribution and Marketing: Xin ZhangSWI swissinfo.ch is a public service media company based in Bern, Switzerland.

Investigadores del Stowers Institute for Medical Research han descubierto que en seres vivos como el gusano plano de tres lineas que tiene la capacidad de regenerarse cuando lo cortan, lo que activa esa regeneracion es el estres que sufre la herida misma. Por tanto, cuando el animal que tiene esta capacidad sufre una lesion, inmediatamente activa una senal biologica que hace que las celulas regeneren la parte perdida.

with Charles Malki of IV OrganicsIn This Episode: Greg interviews Charles Malki, a multifaceted biologist, attorney, author, and inventor, about the innovative benefits of whitewashing trees. Charles details his journey from a passion for plant sciences during his childhood to a career in medicine and law, ultimately leading to the creation of Ivy Organic. He explains the importance of whitewashing for tree protection against weather extremes and pests, emphasizing the environmental benefits of using organic products. The discussion also covers the genesis of Ivy Organics, the science behind their product formulations, and their impact on both small-scale gardeners and commercial orchards. Charles shares valuable personal and professional anecdotes, highlighting the significance of setting clear goals, fostering beneficial relationships, and continually educating oneself and others about sustainable gardening practices.Our Guest:  Charles Malki is a biologist, attorney, all American swimmer, philanthropist, inventor, entrepreneur, and author. He has been published in journals, including the Journal of Surgical Research and American Federation of Medical Research. At the heart of all of his successes is his love of life and his passion to educate others on the limitless topics that rotate to plant sciences, and it all benefits you, your family and friends, community, and our planet.Connect with IV Organics - IVOrganics.comBook recommendations -  Saving the World with the Home Garden by Charles MalkiThe Secret by Rhonda ByrneVisit UrbanFarm.org/IVOrganics for the show notes and links on this episode! Need a little bit of advice or just a feedback on your design for your yard or garden?The Urban Farm Team is offering consults over the phone or zoom. Get the benefits of a personalized garden and yard space analysis without the cost of trip charges. You can chat with Greg, Janis or Ray to get permaculture based feedback.Click HERE to learn more!Become an Urban Farm Patron and listen to more than 900 episodes of the Urban Farm Podcast without ads. Click HERE to learn more.*Disclosure: Some of the links in our podcast show notes and blog posts are affiliate links and if you go through them to make a purchase, we will earn a nominal commission at no cost to you. We offer links to items recommended by our podcast guests and guest writers as a service to our audience and these items are not selected because of the commission we receive from your purchases. We know the decision is yours, and whether you decide to buy something is completely up to you.

In this episode, we discuss long-term outcomes after chest-wall irradiation for breast cancer, new treatments for psoriasis and obesity, and early results on a vaccine for Lassa fever. We review opioid deprescribing and a clinical case describes spiraling into a distant past. Perspectives examine the corporatization of health care, the health effects of new energy legislation, and Medicaid cuts affecting U.S. children.

Dr. Hoffman continues his conversation with Dr. Alan Rozanski, a distinguished Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of Nuclear Cardiology at Mount Sinai St. Luke's in New York City.

Dr. Alan Rozanski, a distinguished Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of Nuclear Cardiology at Mount Sinai St. Luke's in New York City, details the holistic aspects of medicine, emphasizing the integrative approach involving lifestyle, mental health, exercise, and the psychological dimensions of heart health. Dr. Rozanski reveals the six domains of optimal health and vitality, sharing insights from his pioneering work in integrating such approaches into cardiology, the significant impact of stress, and the importance of maintaining a sense of life purpose and social connections. He also delves into modern imaging techniques, the utility of coronary artery calcium scores, and emerging treatments like GLP-1 drugs for cardiovascular health. The conversation provides a thorough exploration of comprehensive health management strategies beyond just medication and surgery.

This week, we look at new findings from the European prostate cancer screening study, advances in lung cancer therapy, physical therapy for meniscal tear, and a promising vaccine for Salmonella Paratyphi A. We review noninvasive liver fibrosis assessment and a complex clinical case, and explore perspectives on concierge care, kidney disease equity, WIC enrollment, community health, FDA regulation, and standing with colleagues in Gaza.

An electronic eye implant half the thickness of a human hair has helped people with incurable sight loss to see again, opening up a potential ‘new era' in tackling blindness. Madeleine Finlay hears from Mahi Muqit, a surgeon from Moorfields eye hospital in London, about what this implant has meant for his patients and what the future could hold for vision-loss therapies. Help support our independent journalism at theguardian.com/sciencepod

In this episode, we look at new research on mucoactive therapy for bronchiectasis, aspirin use in anticoagulated patients with coronary disease, and sotatercept for early pulmonary arterial hypertension. We explore the genetics behind misdiagnosed common diseases and review uncertainty in medical training. We also share a case of woman with abdominal distention, edema, and pleural effusions and Perspectives on sickle cell disease, fetal personhood, and living with a genetic diagnosis.

Ladies, it's Breast Cancer Awareness Month, so go get your boobies checked! We're also talking family lineage, growing up on a farm, and the groundbreaking treatment for Huntington's disease.00:00:00 - Introduction & Getting Started 00:02:04 - Fall Season & Halloween Decorations Debate 00:05:27 - Big Tea & Do Dog (Parent Nicknames) 00:15:27 - Big Family Reflections 00:20:08 - Family Genealogy & Lineage00:24:11 - Pop Culture & Science Discussion00:30:16 - Gene Therapy & Medical Research 00:33:07 - Eric Dane & ALS Awareness 00:37:11 - mRNA Vaccine Technology 00:38:36 - Wrapping Up & Superpower TalkMORE PODCAST EPISODES: https://youtube.com/playlist?list=PLTGuNbPgq2EartAwwgs_H-LVho3FvWnXpJUST LISTEN TO THE PODCAST: https://link.chtbl.com/imomsohardSEE US ON TOUR: (FALL DATES COMING SOON)https://www.imomsohard.com/WATCH OUR AMAZON PRIME SPECIAL: https://www.amazon.com/IMomSoHard-Live/dp/B07VBJ34DTIf you are interested in advertising on this podcast email ussales@acast.comTo request #IMOMSOHARD to be on your Podcast, Radio Show, or TV Show, reach out to talent@pionairepodcasting.comFOLLOW US: Facebook: https://www.facebook.com/imomsohardInstagram: https://www.instagram.com/imomsohard/Twitter: https://twitter.com/imomsohardGet our sponsor DISCOUNT CODES here!https://linktr.ee/imshpodcastABOUT US Female comedy duo Kristin Hensley and Jen Smedley have been performing, teaching, and writing comedy internationally for a combined 40+ years. They have been moms for one quarter of that time and it shows. How do they cope? They laugh about all of the craziness that comes with being a mom and they want you to laugh about it too! From snot to stretchmarks to sleepless nights, Kristin and Jen know firsthand that parenting is a hard job and they invite you to join them in taking it all a little less seriously (even if for a few short minutes a day). After all, Jen currently has four days of dry shampoo in her hair and Kristin's keys are still in her front door. They try, they fail, they support each other, and they mom as hard as they can.Disclaimer: This podcast is for entertainment purposes only. Views expressed on this podcast solely reflect those of the host and do not reflect the views of Pionaire. Hosted on Acast. See acast.com/privacy for more information.